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Abstract 
 1
 Understanding the neurobiology of the transition from initial drug use to excessive drug use 
has been a challenge in drug addiction.  We examined the effect of chronic “binge” escalating 
dose cocaine administration, which mimics human compulsive drug use, on behavioural 
responses and the dopaminergic system of mice and compared it to a chronic steady dose 
(3x15 mg/kg/day) “binge” cocaine administration paradigm.  Male C57BL/6J mice were 
injected with saline or cocaine in an escalating dose paradigm for14 days.  Locomotor and 
stereotypy activity were measured and quantitative autoradiographic mapping of D1 and D2  
receptors, dopamine transporters, and D2-stimulated [35S]GTPγS  binding was performed in 
the brains of mice treated with this escalating  and steady dose paradigm.  An initial 
sensitisation to the locomotor effects of cocaine followed by a dose dependent increase in the 
duration of the locomotor effect of cocaine was observed in the escalating but not the steady 
dose paradigm.  Sensitisation to the stereotypy effect of cocaine and an increase in cocaine-
induced stereotypy score was observed from 3x20 to 3x25 mg/kg/day cocaine.  There was a 
significant decrease in D2 receptor density, but an increase in D2 stimulated G- protein activity 
and dopamine transporter density in the striatum of cocaine treated mice which were not 
observed in our steady dose paradigm.  Our results document that chronic “binge” escalating 
dose cocaine treatment triggers profound behavioural and neurochemical changes in the 
dopaminergic system which might underlie the transition from drug use to compulsive drug 
use associated with addiction, which is a process of escalation. 
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Introduction 
 
Cocaine, one of the most commonly abused psychostimulants induces the elevation of 
extracellular dopamine in the striatum by blocking the dopamine transporter (DAT).  The 
dopaminergic system including D1, D2 dopamine receptors and DAT has been shown to play 
a key role in mediating the locomotor, rewarding, reinforcing, sensitising and stereotypic 
effects of cocaine (for review see Anderson & Pierce (2005)). 
 
In addition, neurochemical data also supports the presence of interactions between cocaine 
and the dopaminergic system.  There are multiple studies investigating the effect of cocaine 
on D1 and D2 receptor and DAT density with inconsistent findings with each other.  Increases, 
decreases or no change in D1 receptor binding, D2 receptor binding  (Taylor et al., 1979; 
Goeders & Kuhar, 1987; Peris et al., 1990; Volkow et al., 1990; Volkow et al., 1993; 
Berrettini et al., 1994; Unterwald et al., 1994; Maggos et al., 1998; Nader & Czoty, 2005; 
Nader et al., 2006; Bailey et al., 2007b) and DAT binding (Kula & Baldessarini, 1991; Sharpe 
et al., 1991; Benmansour et al., 1992; Farfel et al., 1992; Alburges et al., 1993; Cass et al., 
1993; Hurd & Herkenham, 1993; Little et al., 1993; Pilotte et al., 1994; Staley et al., 1994; 
Wilson et al., 1994a; Wilson et al., 1994b; Hitri et al., 1996; Pilotte et al., 1996; Kunko et al., 
1997; Maggos et al., 1997; Little et al., 1998a; Little et al., 1999; Bailey et al., 2007b) have 
been reported.  The lack of concordance in the above studies may arise from differences in 
treatment paradigms (varying doses, schedule and route of administration), length of 
withdrawal of receptor measurement in relation to the last cocaine injection and/or ligands 
used to quantify receptors and DAT.  Nonetheless, a decrease in D2 availability as measured 
with positron emission tomography (PET) in cocaine abstinent humans, non human primates 
and rats has been repeatedly and consistently observed (Volkow et al., 1990; Volkow et al., 
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1993; Tsukada et al., 1996; Maggos et al., 1998; Nader & Czoty, 2005; Nader et al., 2006) 
and is thought to be associated with vulnerability to the reinforcing effects of drugs of abuse. 
 
The aim of our study is to characterise the behavioural and neurochemical effect of cocaine on 
the dopaminergic system of mice treated with an escalating dose “binge” cocaine 
administration paradigm which closely mimics common features of human cocaine abuse and 
to compare that with those of traditionally used chronic steady dose “binge” cocaine 
administration paradigm.  A common feature of human cocaine abuse is the development, 
over time, of tolerance to the reinforcing effects of cocaine, which results in administration of 
increasing doses of cocaine (Koob & Kreek, 2007).  Indeed, novel animal models of 
excessive drug taking in dependent animals have recently been developed which demonstrate 
that rats which are trained to self administer cocaine over a long time, display a number of 
behavioural patterns consistent with those commonly observed in human cocaine addicts, 
including a progressive escalation in drug consumption, elevated drug-directed behaviours 
during extinction/abstinence and increased susceptibility to cocaine induced relapse which are 
thought to be related to the transition to cocaine addiction .  Recent studies have also shown 
dramatic dysregulation of brain reward pathways (Ahmed & Koob, 1998; , 1999; Ahmed et 
al., 2003; Ahmed & Koob, 2004), activation of brain stress systems in the extended amygdala 
(Zorrilla et al., 2001; Mantsch et al., 2003) and profound changes in the μ- (MOP-r) and κ- 
(KOP-r) opioid receptors systems (Bailey et al., 2005; Schlussman et al., 2005; Bailey et al., 
2007a) in animal models of escalating “binge” cocaine administration.  This study was 
designed in order to investigate the effects of this novel chronic escalating dose cocaine 
administration paradigm on locomotion and stereotypy and on the levels of DAT, D1, D2 
receptor binding and D2 stimulated G- protein activity in different brain regions of C57BL/6J 
mice brains and to compare it with traditionally used steady dose administration paradigms.  
The results would give us an insight of possible behavioural and neurochemical changes 
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taking place in the dopaminergic system which might underlie the transition from drug use to 
compulsive drug use associated with addiction, which is a process of escalation.  In addition, 
this is the first study which investigated the effect of chronic cocaine use on D2 receptor G 
protein activity with the use of quinerolane stimulated [35S]GTPγS autoradiography.  These 
results, which may indeed differ from those obtained with D2 receptor binding, may provide 
important information on the biochemical basis of the behavioural sensitisation properties of 
cocaine. 
 
Materials and Methods 
 
Animals and chronic cocaine treatment 
 
6-8 week old C57BL/6J mice, 20-25 g, were studied.  Mice were housed individually in a 
temperature-controlled room, with a 12 h light/dark schedule.  Food and water were available 
ad libitum. All animals were weighed daily throughout the study.  After 7 days of 
acclimatisation, intraperitoneal (i.p.) injections of either saline (1ml/kg) or cocaine were then 
administered in an escalating or steady dose ‘‘binge’’ paradigm to mimic a common pattern 
of self-administration in human cocaine abusers (Tsukada et al, 1996).  Animals in the 
escalating dose group received 15x3 mg/kg/day on days 1–4, 20x3 mg/kg/day on days 5–8, 
25x3 mg/kg/day on days 9–12, and 30x3 mg/kg/day on days 13 and 14.  For animals treated 
with a chronic steady dose “binge” administration paradigm, 15 x 3 mg/kg/day were 
administered for 14 days.  Three i.p. injections (1 h apart) were administered daily, with the 
first injection 60 min after the start of the light cycle.  Animals were randomized into four 
groups of 6-12.  Each group received either saline or cocaine injections for 14 days. Thirty 
minutes after the last injection, animals were killed by decapitation after a 15 second exposure 
to CO2.  Brains were rapidly removed and frozen by immersion for 30 seconds in isopentane 
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cooled to –35°C. All studies were performed in accordance with protocols approved by the 
Home Office (Animals Act 1986) UK. 
 
Cocaine-induced locomotor activity 
 
Locomotor activity was measured by the use of 12 motility chambers (40cm length x 20 cm 
wide x 20 cm height) (Linton Instrumentation, Norfolk, UK).  Each cage had two sets of 16 
photocells located at right angles to each other, projecting horizontal infrared beams 2.5 cm 
apart and 1 and 6 cm above the cage floor. The protocol for locomotor testing was a slight 
modification of that used by Heidbreder et al. (1998).  When mice were tested in the activity 
chambers, they were habituated for 60 min after which they received an i.p. injection of saline 
or cocaine.  The animals were then returned immediately to the chambers where locomotor 
activity was assessed for 60 min. The mice received a second and third injection of saline or 
cocaine 60 min and 120 min respectively after the first one and then returned immediately to 
the chambers where locomotor activity was assessed for 60 min. The locomotor activity for 
each mouse after each of the three daily injections of saline or cocaine was monitored daily 
for a period of 14 days.  Locomotor activity was defined as the activity from measurement of 
sequential infrared beam breaks, recorded every 5 min, beginning immediately after placing 
the animals in the cage following an injection of saline or cocaine and continued for a 60 min 
period.  For measurement of basal activity, mice were habituated for 60 min in the motility 
boxes prior to injections.  Another group of mice were treated with 1 day acute “binge” 
cocaine administration protocol in order to compare the locomotor activity of mice at the end 
of the chronic escalating dose “binge” cocaine administration protocol with those treated 
acutely for 1 day with “binge” cocaine.  Mice received three i.p. injections (1 h apart) of 
cocaine (30 x 3 mg/kg/day) for only 1 day and locomotor activity was measured for 60 min 
after each injection. 
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 Cocaine-induced stereotypy 
 
All mice receiving either saline or cocaine were videotaped twenty minutes after each 
injection for 30 sec.  Videotapes were later rated for stereotypy by a trained observer blind as 
to the animal’s treatment group.  The rating was based on a slight adaptation of the scale used 
by Schlussman et al., (2003) and consisted of a graded scale of drug induced behaviours: 1) 
asleep, inactive; 2) alert, actively grooming; 3) increased sniffing (occasional light sniffing, 
often while exploring the cage); 4) intermittent rearing and sniffing (two or three rears in a 
20s period, with sniffing frequently at the apex of the rear); 5) increased locomotion; 6) 
intense sniffing in one location (rapid sniffing, often with head down is the predominant 
behaviour displayed); 7) continuous pivoting and sniffing (no rearing, no locomotion);  8) 
intermittent rearing and sniffing (intermittent up and down rearing behaviour with 
locomotion); 9) maintained rearing and sniffing (animal remains up on hind legs throughout 
most of the observed period); 10) splayed limbs.  Each animal received a single score 
following each injection, which corresponded to the specific stereotypic behaviour 
predominantly observed during the 30 sec observation period.  The stereotypy behaviour of 
each mouse injected three times daily with saline or cocaine was scored every day for the 14 
days duration of the study.  The median stereotypy score of each mouse on each day was used 
for later analysis. 
 
D1, D2 dopamine receptor and dopamine transporter (DAT) autoradiography 
 
Animals treated with the escalating dose paradigm were killed 30 min following the last 
injection of saline or cocaine on day 14 of the study and the brains were immediately 
removed, quickly frozen in ispentane (-35 oC) and stored at  -80oC until sectioning.  
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Quantitative autoradiography was performed as detailed previously for D1 , D2 dopamine 
receptor binding (Lena et al., 2004) and DAT binding (Javitch et al., 1985) using the general 
procedures of Kitchen et al. (1997).  Adjacent 20 μm coronal sections were cut at a interval of 
300 μm from chronic “binge” saline or cocaine treated mice brains for the determination of 
total and non-specific binding of [3H]SCH-23390 (containing 1 μM mianserin in order to 
block 5-HT2 and 5-HT1c receptor binding sites), [3H]raclopride and [3H]mazindol at D1, D2 
dopamine receptor and DAT, respectively.  Ligand concentrations were 3-4 x Kd with all 
ligands used at a concentration of 4 nM.  Non-specific binding (NSB) was defined in the 
presence of cis-flupenthixol (10 μM), sulpiride (10 μM), or unlabelled mazindol (10 μM) for 
[3H]SCH-23390,  [3H]raclopride and [3H]mazindol binding respectively.  Following binding 
for a period of 90 min, 60 min or 45 min for D1, D2 dopamine receptor and DAT binding 
respectively, and washing in ice cold buffer (6x1 min for D1 and D2 dopamine receptor 
binding and 2x1 min for DAT binding), the slides were apposed to MR film (Kodak) for 4 
weeks.  Sections from chronic “binge” saline and cocaine treated mice were processed 
together in a paired protocol.  Films were developed using 50% Kodak D19 developer.  
Quantitative analysis of brain receptors was performed as detailed previously (Kitchen et al., 
1997; Lena et al., 2004).  Using an MCID image analyser (Image Research, Canada), brain 
structures were identified using the mouse brain atlas of Franklin and Paxinos (1997).  The 
following structures were analysed by sampling 5-10 times with a box tool: cortex (8 x 8 mm) 
and olfactory tubercle (6 x 6 mm).  All the other areas were analysed using freehand drawing 
tool.  The regions analysed include cingulate cortex, nucleus accumbens core, nucleus 
accumbens shell, olfactory tubercle, dorsal endopiriform, dorsolateral caudate putamen, 
dorsomedial caudate putamen, ventomedial caudate putamen, ventrolateral caudate putamen, 
lateral septum and medial septum. 
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Quinelorane-stimulated [35S]GTPγS autoradiography 
 
Quinerolane-stimulated [35S]GTPγS autoradiography was performed essentially as described 
by Newman-Tancredi et al., (2001).  Coronal sections (20 μm thick) were cut in a cryostat at a 
interval of 300 μm from the same chronic “binge” escalating dose treated C57BL/6J mice or 
chronic saline treated mice used for the receptor binding autoradiography described in the 
previous section for the determination of basal, quinelorane-stimulated [35S]GTPγS binding,  
raclopride reversal of quinelorane-stimulated [35S]GTPγS binding, and non-specific binding.  
The same protocol was carried out in brains of mice treated with a chronic steady dose 
cocaine administration paradigm.  Sections were preincubated in assay buffer (50 mM 
Tris/HCl, 3 mM MgCl2.6H2O, 0.2 mM EGTA, 100 mM NaCl, pH7.4 at 25 °C) for 10 min.  
Sections were then incubated in assay buffer containing 2 mM GDP, pH 7.4 at 25 °C for 15 
min.  D2 receptor agonist stimulated activity was determined by incubating the sections in 
[35S]GTPγS (0.04 nM) with the selective D2 receptor agonist quinelorane (100μM) for 2 hours 
in assay buffer containing 2 mM GDP.  Basal G-protein activity was determined by 
incubating the sections in [35S]GTPγS in the presence of GDP (2mM) and in the absence of 
the agonist.  Non-specific binding was assessed by incubating sections in [35S]GTPγS in assay 
buffer containing 2 mM GDP in the presence of 10 μM unlabelled GTPγS.  Reversal of 
quinelorane-stimulated [35S]GTPγS binding was determined by incubating sections in 
[35S]GTPγS in the presence of quinelorane (100μM) and raclopride (10 μM) in assay buffer 
containing 2 mM GDP.  After incubation for 2 h, slides were rinsed twice for 3 min in ice-
cold buffer (50 mM Tris/HCl, pH 7.4 at 0°C) followed by one rinse in de-ionised water.  
Slides were then dried for 2 h in a cold air stream and drying was continued for a further 2 
days using anhydrous calcium sulfate (Drierite, BDHChemicals, Poole, UK).  Sections from 
the brains of chronic cocaine treated mice and chronic saline treated mice were apposed to 
Kodak MR films (Amersham International plc, Buckinghamshire, UK) together with [14C] 
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standards (Amersham) for 3 days.  Quantitative analysis of optical density was performed as 
detailed previously (Schroeder et al., 2003) using [14C] standards.  For each brain region 
examined, [35S]GTPγS binding was calculated by first subtracting the optical density of NSB 
sections from the optical density of  agonist-stimulated, reversal of agonist stimulated or basal 
binding sections.  The regions analysed include nucleus accumbens core, nucleus accumbens 
shell, olfactory tubercle, dorsolateral caudate putamen, dorsomedial caudate putamen, 
ventomedial caudate putamen, ventrolateral caudate putamen, lateral septum and medial 
septum. 
 
Statistics 
 
Cocaine-induced locomotor activity in 5 min data collection bins was analysed by two-way 
analysis of variance (ANOVA) (treatment and day) with repeated measures for day, followed 
by post hoc Newman-Keuls test.  Values were expressed as mean ± S.E.M of total activity per 
5 min bin. The median stereotypy score of each animal on each day was used as the raw data 
for subsequent analysis.  Stereotypy behaviour was analysed by mean ± S.E.M of daily 
median stereotypy score of saline or chonic cocaine-treated mice.  The statistics approach 
used in this case was two-way ANOVA (for factors treatment and day) with repeated 
measures for day, followed by post hoc Newman-Keuls test.  Since the expression of 
behavioural stereotypy was measured with a behavioural rating scale, non parametric Mann-
Whitney U tests were also used in order to confirm results obtained by the ANOVA.  Two-
way ANOVA (for factors region and treatment) was used for comparison of quantitative 
measures (fmol/mg) of  D1, D2 receptors, DAT in brain regions of chronic “binge” saline and 
cocaine treated mice followed by post hoc least significant difference (LSD) test.  
Quinerolane-stimulated [35S]GTPγS binding activity in brain sections of mice was calculated 
as the increase in relative optical density (ROD) above the basal level in each brain region.  
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Comparison of quinerolane-stimulated [35S]GTPγS binding and reversal of this stimulation in 
brains of chronic saline and cocaine-treated mice was carried out using two way ANOVA for 
factors treatment 1 (saline vs cocaine) and treatment 2 (absence of raclopride vs addition of 
raclopride) followed by Newman-Keuls test.  Comparison of quinerolane-stimulated 
[35S]GTPγS binding in the presence and absence of raclopride in each brain region of saline 
and cocaine-treated mice, was carried out using Student’s t-test.  Comparison of basal 
[35S]GTPγS binding in chronic saline and cocaine treated brains were carried out using two 
way ANOVA for factors treatment (cocaine, saline) and region followed by Newman-Keuls 
post hoc test.  Data from all autoradiography experiments were expressed as the mean ± 
S.E.M of each experimental group. 
 
Materials  
 
Cocaine HCl was purchased from Sigma-Aldrich (Dorset, UK);  [3H]SCH-23390 (70 
Ci/mmol), [3H]raclopride (60.1 Ci/mmol), [3H]mazindol (20.6 Ci/mmol) and [35S] GTPγS 
(1250 Ci/mmol) were purchased from Perkin Elmer (Bucks, UK); cis flupenthixol, sulpiride, 
raclopride, quinerolane, GDP, GTPγS and mazindol were purchased from Sigma-Aldrich.  
 
Results 
 
Locomotor activity during chronic escalating and steady dose “binge” cocaine administration 
 
Locomotor activity of naïve C57BL/6J mice (before saline or cocaine treatment) was 
measured for 60 min after placement in the locomotor chambers. The last 5 min of the 60 min 
duration on day 1 is shown in Fig. 1.  One-way ANOVA, did not show any significant effect 
on basal locomotor activity between the two groups on day 1 (P>0.05).  Basal locomotor 
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activity between the two treatment groups were measured during the 14 days of the study.  
Greater basal locomotor activity was observed in the cocaine treated group compared to saline 
on days 2-14 (P<0.01) (Fig. 1).  
 
Locomotor activity of C57BL/6J mice was measured after each of the three hourly daily 
injections of saline or cocaine (15-30 x 3 mg/kg/day) from day 1 to day 14 of the chronic 
escalating dose “binge” cocaine treatment (Fig. 1a).  Two-way ANOVA showed a significant 
main effect treatment (P<0.0001) and day (P<0.0001) and treatment x day interaction 
(P<0.0001).  Mice treated with cocaine had greater locomotor activity compared to saline on 
all treatment days (P<0.0001, Newman-Keuls post hoc test) (Fig.1a).  A significant increase 
in cocaine-induced locomotor activity was observed on day 3 (15 x 3 mg/kg/day) compared to 
day 1 (15 x 3 mg/kg/day) (P<0.0001) indicating the presence of behavioural sensitisation to 
the locomotor-stimulating effect of cocaine.  Moreover an increase in cocaine-induced 
locomotor activity was observed on day 5 (20 x 3 mg/kg/day) vs day 1 (P<0.0001), day 9 (25 
x 3 mg/kg/day) vs day 5 (P<0.01), and day 13 (30 x 3 mg/kg/day) vs day 9 (P<0.01) 
indicating that the increase in cocaine-induced locomotion is dose dependent.  Both the 
magnitude and the duration of the cocaine response was enhanced on day 3 compared to day 
1.  However, although the magnitude of the cocaine response did not increase, a dramatic 
increase in the duration of cocaine-induced hyperactivity was observed following the increase 
of the cocaine dose from 20 to 25 mg/kg/inj and from 25 to 30 mg/kg/inj (Fig. 1a).  On day 5, 
activity of the cocaine-injected animals returned to baseline levels 60 min after each of the 
three cocaine injections.  However, on day 13 the activity of cocaine-injected animals 
remained constantly elevated at its peak magnitude during the whole 60 min after each of the 
three cocaine injections (Fig.1a).   
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Another group of mice were injected with 30 x 3 mg/kg/day cocaine at 1 h intervals for only 1 
day to compare locomotor activity of mice on day 13 (30 x 3 mg/kg/day) of the escalating 
dose “binge” cocaine administration and after acute (1 day) “binge” cocaine administration 
(30 x 3 mg/kg/day).  In contrast with the chronic paradigm where the duration of the peak 
cocaine response persisted for at least 60 min after cocaine administration, the activity of 1 
day acute cocaine treated animals (3x30 mg/kg) returned to baseline 60 min after each of the 
three cocaine injections (Fig. 1a).  
 
Other groups of mice were treated with a steady dose (3x15 mg/kg/day) cocaine 
administration protocol for 14 days (Fig. 1b).  Cocaine increased locomotor activity compared 
to saline every day during the 14 day duration of the study (P<0.001, Newman-Keuls post hoc 
test).  A significant increase in cocaine induced locomotor activity was observed on day 3 
compared to day 1 (P<0.001) which persisted up to day 5 indicating the presence of 
behavioural sensitisation to the locomotor effect of cocaine (Fig. 1b).  A reduction in cocaine-
induced locomotor activity was observed on day 9 and day 13 vs day 5 of our chronic steady 
dose paradigm (Fig. 1b).  In contrast to the escalating dose paradigm, the activity of cocaine 
injected animals returned to baseline levels 60 min after each of the three cocaine injections 
every day during the 14 day duration of the study (Fig. 1b).   
 
Stereotypy behaviour during chronic escalating and steady dose “binge” cocaine 
administration 
 
Stereotypy activity of C57BL/6J mice was scored 20 min after each of the three injections of 
saline or cocaine every day for the whole duration of the study and the median score of the 
three daily injections have recorded (Fig. 2).  For the escalating dose group, two-way 
ANOVA showed a significant main effect of treatment (P<0.0001), day (P<0.0001) and 
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significant treatment x day interaction (P<0.0001).  Newman-Keuls post hoc test showed that 
escalating dose “binge” pattern cocaine administration resulted in a significant expression of 
behavioural stereotypy (P<0.0001) compared to saline controls (Fig. 2a).  A significant 
increase in cocaine-induced stereotypy was observed on day 3 (15 x 3 mg/kg/day) compared 
to day 1 (15 x 3 mg/kg/day) (P<0.0001) indicating the presence of behavioural sensitisation to 
the stereotypy-stimulating effect of cocaine.  Moreover an increase in cocaine-induced 
stereotypy behaviour was observed on day 5 (20 x 3 mg/kg/day) vs day 1 (P<0.0001), day 9 
(25 mg/kg/day) vs day 5 (P<0.05), but not on day 13 (3 x 30 mg/kg/day) vs day 9 (P>0.05).  
As far as the steady dose group is concerned, cocaine increased stereotypy behaviour every 
day during the 14 day duration of the chronic steady dose (3 x 15 mg/kg/day) cocaine 
administration study compared to saline control (P<0.001) (Fig. 2b).  A significant increase in 
cocaine-induced stereotypy was observed on day 3 compared to day 1 which persisted for the 
rest of the duration of the study indicating the presence of behavioural sensitisation to the 
stereotypy stimulatory effect of cocaine (Fig. 2b).  In contrast to the escalating dose paradigm, 
no increase in cocaine-induced stereotypy behaviour was observed on day 9 vs day 5 (P>0.05) 
(Fig. 2b).   
 
D1, D2 dopamine receptor and dopamine transporter (DAT) autoradiography during chronic 
escalating dose “binge” cocaine administration 
 
For D2 dopamine receptor binding, two way ANOVA showed a significant main effect of 
treatment (P < 0.001).  LSD post hoc test showed significantly lower levels of D2 binding in 
the dorsolateral, dorsomedial, ventrolateral and ventromedial (P<0.001) areas of the caudate 
putamen as well as in the nucleus accumbens core and shell (P<0.05) of cocaine-treated mice 
compared to controls (Figs. 3, 4A).   For DAT binding, two way ANOVA also showed a 
significant main effect of treatment (P < 0.001).  In contrast to D2 binding, significantly 
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higher levels of DAT binding were observed in the nucleus accumbens shell (P<0.01) and 
core (P<0.01), in the olfactory tubercle (P<0.01) and in all regions the caudate putamen 
(P<0.05) of chronic cocaine-treated mice compared to saline controls (Figs. 3, 4B).  There 
was no significant treatment effect on D1 binding (Fig. 3, 4C) (P>0.05). 
 
 Quinelorane-stimulated [35S]GTPγS autoradiography during chronic escalating and steady 
dose “binge” cocaine administration 
 
Quinerolane (100 μM) stimulated [35S]GTPγS autoradiography was performed in coronal 
brain sections of chronic saline or cocaine-treated mice in order to investigate whether there 
were any alterations in D2 receptor stimulated G- protein activity after chronic escalating or 
steady dose “binge”  cocaine administration.  In saline and cocaine-treated animals, 
quinerolane-stimulated [35S]GTPγS binding was observed in the nucleus accumbens, caudate 
putamen, tubercle and septum (Figs. 5 and 6).  The level of stimulation was weakest in the 
lateral septum and medial septum (around 15% over basal) but was over 50% above basal in 
the caudate putamen (data not shown).  In the escalating dose groups, adjacent sections were 
also treated with [35S]GTPγS in the presence of both quinerolane (100μM) and the selective 
D2 receptor antagonist raclopride (10 μM) in order to  investigate whether the stimulation of 
G- protein binding by quinerolane is D2 receptor dependent.  Two-way ANOVA for factors 
treatment 1 (saline, cocaine) and treatment 2 (raclopride reversal in the presence of raclopride,  
no raclopride reversal) with repeated measures for the last variable, showed a significant main 
effect of treatment 2 (P<0001) and a significant treatment 1 x treatment 2 interaction 
(P<0.05).  Newman-Keuls post hoc test showed that raclopride significantly reversed the 
stimulation of [35S]GTPγS binding in response to quinerolane (Fig.5, 6a) both in saline 
(P<0.001) and chronic escalating dose cocaine (P<0.001) treated groups. The significant 
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reversal effect of raclopride in each individual region can be observed in Fig.6a.  Moreover, 
an overall increase in quinerolane-stimulated [35S]GTPγS binding was observed in escalating 
dose cocaine-treated brains compared to saline controls (P<0.05, Newman-Keuls).  A 
significant increase in quinerolane-stimulated [35S]GTPγS binding was observed in the 
nucleus accumbens shell and the ventrolateral area of the caudate putamen of escalating dose 
cocaine-treated animals compared to saline controls (Fig. 6a) (P<0.05, Student’s t test).  No 
change in quinerolane-stimulated [35S]GTPγS binding was observed in any brain region of 
chronic steady dose cocaine (3 x 15 mg/kg/day for 14 days) treated mice compared to saline 
control (P>0.05) (Fig. 6b).   
 
Two-way ANOVA for factors treatment and region of the basal [35S]GTPγS data for 
escalating dose treated animals revealed significantly higher overall levels of basal 
[35S]GTPγS binding in cocaine treated mice brains compared to saline controls  (P=0.05) 
(data not shown).  However, there was no significant increase in basal [35S]GTPγS binding in 
any of the individual regions analysed (P>0.05).  Despite of this, there was still a significant 
increase in quinerolane stimulated [35S]GTPγS binding in cocaine treated brains compared to 
saline controls.  There was no treatment effect in brains on basal G protein activity of steady 
dose cocaine treated mice compared to saline controls (P>0.05) (data not shown). 
 
Discussion 
 
The behavioural results obtained in this study indicate the initial presence of locomotor 
sensitization to the locomotor effect of cocaine, followed by a dose dependent increase in the 
duration but not the magnitude of the locomotor activating effect of cocaine.  In our 
locomotor paradigm of chronic “binge” cocaine administration, behavioural sensitisation 
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could be reflected by the increase in the magnitude (maximum or peak response) as measured 
by increased amount of counts at the time point where the counts are maximal (peak counts) 
or by increased duration of the locomotor effect of cocaine.  Indeed in our escalating dose 
paradigm (see Fig. 1a) an increase in the peak locomotor effect of cocaine in day 3 compared 
to day 1 and an increase in the duration of the cocaine effect on day 13 (without observing an 
increase in the peak response to cocaine) compared to day 3 were observed, which is an 
indication of behavioural sensitisation.  However, in our steady dose paradigm, an increase in 
the peak locomotor effect of cocaine was observed in day 3 compared to day 1 (initial 
sensitisation), but a decrease in the peak locomotor effect of cocaine was observed in day 13 
compared to day 3 without alteration of the duration of the locomotor effect of cocaine, which 
indicates a lack of sensitisation effect at that time point.  These results suggest an increase of 
behavioural sensitisation on day 13 of our escalating dose cocaine administration paradigm 
but not in our steady dose paradigm.  These results are in agreement with Foltin et al., (2003) 
who compared the effects of escalating doses of smoked cocaine with a fixed dosing group in 
humans.  They demonstrated a dose-dependent increase in heart rate, blood pressure, ratings 
of positive drug effect in the escalating dose group and a maintenance of the initial cocaine 
effect throughout the whole study in the fixed group.  Together these results demonstrate that 
increasing the dose of cocaine during a “binge” of cocaine use can increase the effect of 
cocaine, but administering the same cocaine dose maintains, but not increases the effect of 
cocaine suggesting the presence of different neurobiological mechanisms that underlie the 
transition from drug use to compulsive drug use associated with addiction, which is a process 
of escalation.   
 
The initial sensitization effect of cocaine observed in our study is in agreement with the 
development of locomotor sensitization observed in C57BL/6J mice in our study and in others 
using a  14 day steady dose “binge” pattern (15 x 3 mg/kg/day) cocaine administration 
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paradigm (Unterwald et al., 1994; Bailey et al., 2007a), but in contrast with Schlussman et al., 
(2003) who showed tolerance to the locomotor effect of cocaine in C57BL/6J mice treated the 
same chronic steady dose “binge” paradigm as above, in their home cage.  This discrepancy is 
likely to be due to the different environment where the drug was administered during the 
chronic “binge” paradigm (home cage vs novel environment).  Indeed, it has been reported 
that sensitisation is more robust when cocaine is repeatedly administered outside the home 
cage than in the home cage (Badiani et al., 1995; Browman et al., 1998; Uslaner et al., 2003).  
As a result, the increase in the duration of cocaine action observed in days 9-14 of our 
escalating dose paradigm is unlikely to be due to a dose effect rather than sensitization as we 
did not observe any increase in the duration of the cocaine effect when mice were treated with 
an acute 3 x 30 mg/kg (Fig 1a) or during any day of the 14 day steady dose cocaine (3 x 15 
mg/kg/day) administration paradigm.  This is in agreement with Daunais and McGinty (1995) 
who found no differences in the behavioural rating scores of male Wistar rats which received 
30 or 60 mg/kg of cocaine in daily “binges”, suggesting that the expression of behavioural 
activity has reached a maximum at the relatively high dose of 15 mg/kg/injection.  As a result, 
other factors such as the dysregulation of the dopaminergic system may account for the 
locomotor effects of chronic “binge” escalating dose cocaine administration. 
 
In accordance with the locomotor activity data, behavioural sensitization to the stereotypy 
inducing effect of cocaine, followed by an increase in magnitude of stereotypy score on day 9 
compared to day 5, but not on day 13 vs day 9 where the stereotypy effect of cocaine seems to 
reach saturation, was observed in our escalating dose study.  An initial sensitisation was 
observed on day 3 of our steady dose paradigm which persisted throughout the rest of the 
duration of the study.  These findings are in contrast with studies showing a lack of 
sensitisation to the stereotypy behaviour during an identical 14 day “binge” escalating dose 
cocaine administration paradigm in rats (Schlussman et al., 2005) and during a 14 day steady 
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dose (15 x 3 mg/kg/day) “binge” cocaine administration in rats (Schlussman et al., 2005) and 
C57BL/6J mice (Schlussman et al., 2003; Bailey et al., 2007a).  This divergence is again 
likely to be due to the different environment where the drug was administered during the 
chronic “binge” paradigm reinforcing the importance of home cage vs novel environment.   
 
As discussed above, there is a profound difference in the behavioural effect of cocaine when 
administered in a chronic “binge” escalating dose  (15-30 x 3 mg/kg/day) paradigm compared 
to a chronic ”binge” steady dose (15 x 3 mg/kg/day) paradigm.  We hypothesised that these 
changes might be due to profound alterations in the dopamine neurotransmission during 
escalation of cocaine administration which may not take place during steady dose 
administration.  In support of this, Ahmed et al., (2003) showed that rats which escalate their 
intake of cocaine maintain greater levels of dopamine in the nucleus accumbens and are more 
sensitive to the actions of the selective dopamine antagonist cis-flupenthixol than rats which 
had limited access to the drug (steady dose) and that this phenomenon is not associated with a 
change in cocaine pharmacokinetics or efficacy.  The above findings support the hypothesis 
that a decrease in dopamine neurotransmission contributes to escalation of cocaine self 
administration. 
  
Although there have been numerous studies investigating the effect of chronic cocaine 
administration on D1, D2 dopamine receptor and DAT with conflicting results (see 
introduction), this is the first study which has investigated the effects of cocaine administered 
in a chronic “binge” escalating dose pattern which more closely mimics human drug abuse, 
on D1, D2 dopamine receptor, DAT binding and D2 stimulated G protein activity.  A 
significant decrease in D2 receptor density was observed in all regions of the striatum of 
cocaine-treated mice compared to saline controls.  This is in agreement with the consistent 
finding of a decrease in D2 receptor availability and binding as measured by PET and in vitro 
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autoradiography in the brains of cocaine abstinent humans, non human primates and rats 
(Volkow et al., 1990; Volkow et al., 1993; Moore et al., 1998; Nader et al., 2002; Nader & 
Czoty, 2005; Nader et al., 2006) and could reflect receptor downregulation from the exposure 
to a higher extracellular dopamine concentration due to chronic blockade of dopamine 
transporters.  Moreover, and in accordance with Ahmed et al., (2004), this decrease in D2 
receptors may be indicative of a “hypodopaminergic” system which is in need of escalating 
doses of cocaine to maintain increased levels of dopamine in the nucleus accumbens.  
Interestingly, our results are in contrast with those from our group (Bailey et al., 2007b) and 
others (Unterwald et al., 1994) who showed a lack of decrease in D2 receptor binding when 
using a 14 day steady dose “binge” cocaine (15 x 3 mg/kg/day) administration paradigm, 
suggesting that cocaine-induced changes in D2 receptors is dependent on the paradigm used 
(steady vs escalating).  This is in agreement with Nader and Czoty, (2005) who showed that 
duration of exposure and dose of the drug are important factors which affect D2 receptor 
density in brains of monkeys self administering cocaine. 
 
In order to investigate whether the decrease in D2 receptor binding was of any functional 
significance, we measured D2 receptor G protein activity with the use of quinerolane 
stimulated [35S]GTPγS autoradiography in the brains of the same animals in which D2 
receptor binding was measured, in order to obtain a completely paired result.  In contrast to 
the D2 receptor density data, an overall significant increase in quinerolane stimulated 
[35S]GTPγS binding was observed in the brains of chronic “binge” escalating dose cocaine-
treated mice compared to saline controls, with a marked regional significant increase in the 
nucleus accumbens shell and the ventromedial area of the caudate putamen.  No change was 
observed  in quinerolane-stimulated [35S]GTPγS binding brains of steady dose cocaine treated 
mice compared to saline controls in any regions analysed.  These results show the importance 
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of determining functional activity of receptor systems, demonstrating that downregulation of 
receptors does not necessarily translate into loss of functional coupling.  Indeed, we showed 
that while no change in μ- opioid receptor (MOP-r) density was observed in brains of 
morphine withdrawn mice deficient in the A2A receptor compared to wild types, there was an 
enhancement in MOP-r stimulated [35S]GTPγS binding in the nucleus accumbens of these 
mice (Bailey et al., 2004).  The increase in D2 receptor coupling to G protein activity in the 
brains of chronic “binge” escalating cocaine treated mice suggests that chronic cocaine 
treatment increases D2 receptor sensitivity by increasing D2 receptor coupling rather than 
increasing D2 receptor surface receptors.  This is accordance with studies showing that 
locomotor and stereotypy responses to D2 receptor agonists are greater in cocaine-sensitized 
rats than in saline treated controls (Ujike et al., 1990; De Vries et al., 2002).  In addition our 
results are in agreement with Seeman et al. (2007) who showed a 2.2 fold increase in the 
guanine-nucleotide-sensitive component of D2 receptor binding in amphetamine sensitized 
rats.  This confirms the increase in D2 receptor G protein activity in psychostimulant 
sensitized animals with another psychostimulant, by a different method and ligands and in 
different species, even though the total D2 receptor density is significantly decreased.  The 
maintained elevated locomotor activity observed on day 13 of the escalating dose paradigm 
could partially be explained by the increase in D2 receptor activity and thus the increase in D2 
receptor sensitivity observed in these mice.  This is the first study which provides biochemical 
evidence for the increase of sensitivity of D2 receptors following chronic escalating dose 
“binge” cocaine treatment despite the decrease of D2 receptor density.   
 
The increase in D2 receptor coupling to G protein in our study is unlikely to be due to increase 
in pertussis toxin sensitive G protein (Gi/o) which couples to D2 receptors as it has been shown 
that cocaine decreases Gi/o in the nucleus accumbens of rats (Nestler et al., 1990).  Alterations 
of other factors downstream of the receptor affecting Gi/o coupling to D2 receptors in response 
 21
to chronic cocaine administration might play an important role.  For instance alterations in G- 
protein coupled receptor kinase 6 (GRK6), which is known to be involved in D2 receptor 
desensitisation, might be a possible candidate, as enhanced G protein coupling to D2 receptors 
and augmented locomotor responses to cocaine was observed in mice deficient in GRK6 
(Gainetdinov et al., 2003).  The mechanism involved in the increase in D2 receptor coupling 
in escalating dose cocaine treated mice is not clear.  It could be the result of a homeostatic 
response to the decreased D2 receptor numbers observed after chronic cocaine administration.  
Another possibility is that the increase in presynaptic D2 receptor coupling would result in 
reducing dopamine release and thus contribute to the “hypodopaminergic” state which is 
indicative of escalating dose cocaine administered animals. 
 
As quinerolane has been shown to bind to D2 receptors as well as D3 receptors with high 
affinity (Gackenheimer et al., 1995), there is a possibility that the increase in quinerolane 
stimulated [35S]GTPγS binding reflects increases of not only D2 receptor G protein activity but 
also of D3 receptors.  However, the fact that quinerolane-induced stimulation was observed in 
regions of known high D2 receptor density and not in regions of high D3 receptor density 
(islands of Calleja, the bed nucleus of stria terminallis), and that quinerolane stimulation was 
completely abolished by the highly selective D2 receptor antagonist raclopride, indicate that 
the increase in quinerolane stimulated [35S]GTPγS binding observed in our study is attributed 
to D2 receptors rather than D3 receptors.  In support of this, previous behavioural and 
biochemical data showed that selective D3 and D4 antagonists did not block quinerolane 
induced turning behaviour and [35S]GTPγS binding in the rat (Newman-Tancredi et al., 2001). 
 
In addition to the opposite changes in D2 receptor binding and activity observed in our study, 
a significant increase in DAT binding was observed in the striatum of mice treated with a 
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chronic “binge” escalating dose cocaine administration paradigm.  This is in agreement with 
studies showing increases in the DAT binding and/or dopamine uptake in brains of human 
cocaine abusers (Staley et al., 1994; Little et al., 1998b; Little et al., 1999; Mash et al., 2002), 
in rodents which self administer cocaine (Wilson et al., 1994a) and in rodents which have 
been chronically treated with cocaine (Pilotte et al., 1994; Claye et al., 1995; Hitri et al., 
1996).  This increase in the numbers of DAT following chronic cocaine administration might 
reflect a compensatory change to modify synaptic dopamine concentration in the striatum and 
to maintain dopaminergic neurotransmission at more normal levels.  Indeed, as cocaine 
elevates dopamine by blocking reuptake into the presynaptic terminal, one way to compensate 
for the effect of cocaine would be to enhance the uptake and transport of dopamine across the 
dopaminergic presynaptic membrane by increasing DAT density.  Such increases in DAT 
might not only contribute to the dopaminergic deficit believed to occur in the brain of 
escalating dose cocaine self administration (Ahmed et al., 2003; Ahmed & Koob, 2004), but 
might also contribute to cocaine withdrawal symptoms that cocaine abusers experience such 
as depression and suicidability and thus might sustain the rewarding effect of cocaine 
bingeing (Little et al., 1999).   
 
A possible mechanism by which chronic escalating dose cocaine administration might 
increase DAT density is by the activation of the D2 receptors observed in our study.  While 
Parson et al., (1993) demonstrated that D2 receptor antagonists prevents the upregulation of 
dopamine uptake that results from chronic intermittent cocaine administration, Mayfield and 
Zahniser., (2001) found that activation of D2 receptors via the Gi/o coupling results in an 
increased number of DAT sites.  Interestingly, in contrast to our data, a lack of change in 
DAT density was observed in C57BL/6J mice treated with a 14 day “binge” steady dose (15 x 
3 mg/kg/day) administration protocol (Bailey et al., 2007b).   
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In contrast with DAT and D2 receptor density and activity, there was no change in D1 receptor 
density in the brains of escalating dose cocaine treated mice compared to saline controls.  
Although there is a large body of literature suggesting an important role for D1 receptors in 
the expression of cocaine sensitisation (for review see Anderson and Pierce (2005), Spanagel 
(1995) and Unterwald et al., (1994), the lack of D1 receptor changes in our study suggests that 
D1 receptor numbers might not play a role in our escalating pattern of cocaine administration.  
These results are in accordance with a previous study in this lab (Bailey et al., 2007b) which 
failed to find any significant change in D1 receptor binding in a 14 day steady dose “binge” 
cocaine administration paradigm.  However, a lack of change in D1 receptor numbers does not 
exclude changes in D1 receptor G protein coupling and in second messenger transmission 
downstream from the receptor.  Moreover, D1 receptors might play an important role in the 
initiation (early stage) of sensitisation, but not in the later stage of compulsive escalating drug 
abuse. 
 
Finally, the lack of changes in D2, D2 stimulated [35S]GTPγS and DAT binding in the steady 
dose cocaine treated mice together with the profound changes observed in D2, D2 stimulated 
[35S]GTPγS and DAT binding in the brains of escalating dose cocaine treated mice, suggest 
the presence of different neurobiological mechanisms that underlie the transition from drug 
use to compulsive drug use associated with addiction, which is a process of escalation.  
Furthermore, our results together with others indicate that our chronic “binge” escalating dose 
cocaine administration paradigm is a more appropriate model to study drug abuse as both the 
behavioural and biochemical alterations observed in this model more closely mimics those 
observed in human cocaine abusers.   
 
Legend to Figure 1.  Locomotor activity in C57BL/6J mice after saline or cocaine treatment 
during a chronic “binge” a) escalating dose and b) steady dose administration paradigm.  The 
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locomotor data were collected daily in 5 min bins following each of the three injections of a 
14 day “binge” escalating dose (15-30 x 3 mg/kg/day, i.p.) or steady dose (15 x 3 mg/kg/day, 
i.p.) pattern of cocaine or saline.  Representative responses are shown from day 1, day 3, day 
5 and day 13.  The locomotor activity of one group of C57BL/6J mice treated for one day 
with an acute “binge” cocaine administration paradigm (30 x 3 mg/kg/day) is seen in the 
bottom right corner of the figure.  Values are mean ± S.E.M of 6-12 animals in each group.  
Two-way ANOVA showed a significant main effect of treatment (P<0.0001), day (P<0.0001) 
and treatment x day interaction (P<0.0001) for both escalating and steady dose paradigms.  
There was an increase in basal locomotion in the cocaine treated groups vs saline control on 
days 2-14 (P<0.01) on the treatment paradigm in the escalating dose group.  Significant 
asterisks were omitted from the graph for clarity of presentation.  
 
Legend to Figure 2.  Daily stereotypy scores in C57BL/6J mice following chronic “binge” a) 
escalating dose and b) steady dose cocaine administration.  The stereotypy score assigned to 
each animal was based on its median stereotypy score of the three daily injections of “binge” 
pattern cocaine or saline administration recorded 20 min after each of injection.  Values are 
mean ± S.E.M of 6 animals in each group.  Two way ANOVA showed a significant main 
effect of treatment (P<0.0001), day (P<0.0001) and significant treatment x day interaction 
(P<0.0001) for both escalating and steady dose treatment.  Cocaine administration resulted in 
a significant expression of behavioural stereotypy (P<0.0001) 
 *** P<0.001 vs day 1, #P<0.05 vs day 5 (Newman-Keuls post hoc test) 
 
Legend to Figure 3.  Computer-enhanced autoradiograms of coronal brain sections from 
chronic “binge” escalating dose cocaine or saline treated C57BL/6J mice. The adjacent 
sections shown are from the level of the caudate (Bregma 1.10 mm).  D1, D2 dopamine 
receptor and dopamine transporters (DAT) were labelled with [3H]SCH-23390 (4 nM), 
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[3H]raclopride (4 nM) and [3H]mazindol (4 nM), respectively.  Non-specific binding (NSB) 
was defined in the presence of cis-flupenthixol (10 μM), sulpiride (10 μM), or unlabelled 
mazindol (10 μM) for [3H]SCH-23390,  [3H]raclopride and [3H]mazindol binding 
respectively. The colour bar represents a pseudo-colour interpretation of black and white film 
images in fmol/mg tissue equivalent.  Sections cut from chronically cocaine and saline treated 
C57BL/6J brains were processed in parallel. 
  
Legend to Figure 4.  Quantitative autoradiography of D1, D2 dopamine receptor and dopamine 
transporters binding in coronal brain sections from chronic “binge” escalating dose cocaine 
and saline treated C57BL/6J mice.  Data are expressed as the mean specific binding 
(fmol/mg)  ± S.E.M of 5-10 determinants  of A) [3H]raclopride, B)  [3H]mazindol and C) 
[3H]SCH-23390 in brain regions of  chronically cocaine or saline treated C57BL/6J mice.  
The labelling was carried out on sections from chronically cocaine or saline treated C57BL/6J 
mice in a completely paired protocol.  Specific binding was >80 % in all regions analysed.  
Two way ANOVA showed a significant main effect of treatment (P < 0.001) for 
[3H]mazindol binding  and [3H]raclopride binding, but not for  [3H]SCH-23390 binding. 
* P<0.05, ** P<0.01, *** P<0.001 vs saline controls (LSD post hoc test). Abbreviations:  
CgCx, Cingulate cortex; AcbC, Nucleus accumbens core; AcbSh, Nucleus accumbens shell; 
Tu, Olafactory tubercle; Den, Dorsal endopiriform; DLCPu, Dorsolateral caudate putamen; 
DMCPu, Dorsomedial caudate putamen; VMCPu, Ventomedial caudate putamen; VLCPu, 
Ventrolateral caudate putamen; LS, Lateral septum; MS, Medial septum 
 
 
Legend to Figure 5.  Computer-enhanced autoradiograms of coronal brain sections from 
chronically “binge” escalating dose cocaine and saline treated C57BL/6J mice.  The sections 
shown are from the level of the caudate (Bregma 1.10 mm)   Sections were preincubated with 
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2 mM GDP and then incubated for 2 h with [35S]GTPγS (0.04 nM) and 2 mM GDP (basal), 
[35S]GTPγS (0.04 nM) and 2 mM GDP in the presence of quinerolane (100 μM) (quinerolane 
stimulated [35S]GTPγS), [35S]GTPγS (0.04 nM) and 2 mM GDP in the presence of 
quinerolane (100 μM) and raclopride (10 μM) (reversal of quinerolane stimulated 
[35S]GTPγS)  or with [35S]GTPγS (0.04 nM) and 2 mM GDP in the presence of 10μM 
unlabelled GTPγS (non-specific binding, NSB).  The colour bar represents a pseudo-colour 
interpretation of relative black and white film images.   Sections cut from chronically “binge” 
saline and cocaine treated mice brains were processed in parallel. 
 
Legend to Figure 6.  Quinerolane stimulated [35S]GTPγS binding in coronal brain sections 
from chronically “binge” a) escalating dose and b) steady dose cocaine and saline treated 
C57BL/6J mice.  Data are expressed as mean ± S.E.M (n=6-12) of [35S]GTPγS stimulation 
expressed as increase in relative optical density (ROD) above basal.  Two way ANOVA 
showed a significant main effect of raclopride (reversal) (P < 0.001) and a significant 
raclopride x treatment (saline, cocaine) interaction  (P<0.05) in the escalating dose group.  
There was an overall increase in quinerolane stimulated [35S]GTPγS binding in the escalating 
dose cocaine treated mice compared to saline controls (P<0.05).  No cocaine effect was 
observed in the steady dose group. 
# P<0.05, ## P<0.01, ### P<0.001 vs D2 stimulated [35S]GTPγS binding in the cocaine group; * 
P<0.05 vs D2 stimulated [35S]GTPγS binding in the saline group (Student’s t test).  
Abbreviations:  AcbC, accumbens core; AcbSh, accumbens shell; Tu, olfactory tubercle; 
DLCPu, Dorsolateral caudate putamen; DMCPu, Dorsomedial caudate putamen; VMCPu, 
Ventomedial caudate putamen; VLCPu, Ventrolateral caudate putamen; LS, Lateral septum; 
MS, Medial septum 
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